Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Other Non-Current Liabilities (2019 - 2025)

AVITA Medical's Other Non-Current Liabilities history spans 6 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 63.78% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 63.78%, while the annual FY2025 figure was $1.2 million, 63.78% down from the prior year.
  • Other Non-Current Liabilities reached $1.2 million in Q4 2025 per RCEL's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.0 million in Q1 2024 to a low of $19000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $1.7 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: surged 2905.26% in 2022, then crashed 63.78% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $113000.0 in 2021, then skyrocketed by 1092.92% to $1.3 million in 2022, then soared by 134.27% to $3.2 million in 2023, then increased by 8.68% to $3.4 million in 2024, then plummeted by 63.78% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Other Non-Current Liabilities are $1.2 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025).